晚期高级别B细胞淋巴瘤的临床结局、复发模式及分子特征
研究纳入124例晚期高级别B细胞淋巴瘤(HGBCL)患者,比较不同基因重排组合的预后。结果证实HGBCL预后差,完全缓解率44%,2年总生存率59.8%,中枢神经系统复发率10.1%。MYC/BCL6重排患者中枢复发风险高且复发后快速死亡,支持将其作为独立临床实体。
要点
- HGBCL完全缓解率44%,2年总生存率59.8%,中枢神经系统复发率10.1%。
- MYC/BCL6重排患者中枢复发发生率更高,复发后快速进展至死亡。
- 剂量调整R-EPOCH等强化方案较R-CHOP方案总生存改善。
核心结论
- 证实HGBCL预后差,完全缓解率低、总生存短且中枢复发率高。
- MYC/BCL6重排疾病中枢复发风险高且复发后快速死亡,支持将其作为独立临床实体。
研究设计与样本
- 回顾性分析Memorial Sloan Kettering Cancer Center的124例晚期HGBCL患者临床数据。
- 其中69例MYC/BCL2-R,34例MYC/BCL2/BCL6-R(三打击),21例MYC/BCL6-R。
主要发现
- 完全缓解率44%,2年总生存率59.8%,中枢神经系统复发率10.1%。
- MYC/BCL6-R患者中枢复发发生率增加且复发后快速进展至死亡。
- MYC/BCL6-R与BCL2-R疾病的细胞起源不同。
- 由低级别淋巴瘤转化的HGBCL在本队列中与生存改善相关。
- 突变谱显示富集DLBCL相关突变(尤其生发中心来源病例)及高比例MYC突变。
临床怎么用
- 对晚期HGBCL应关注中枢神经系统复发风险,尤其MYC/BCL6-R患者。
- 强化方案如剂量调整R-EPOCH可能较R-CHOP方案改善总生存。
- MYC/BCL6-R可考虑作为独立临床实体进行管理。
局限性
- 回顾性单中心研究,样本量有限(124例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
High-grade B-cell lymphoma (HGBCL) is an aggressive clinical entity characterized by poor overall survival and high rates of central nervous system (CNS) relapse. HGBCL includes cases harboring MYC rearrangement with concurrent BCL2 and/or BCL6 rearrangements (BCL2-R and/or BCL6-R). However, the prognostic implications of different rearrangements combinations (MYC/BCL2, MYC/BCL6, or MYC/BCL2/BCL6) remains an open question, with differing reports in the literature, and our knowledge of the clinical characteristics, response to treatment, and patterns of relapse remains incomplete. We identified clinical data from 124 subjects with advanced-stage HGBCL treated at Memorial Sloan Kettering Cancer Center (69 MYC/BCL2-R, 34 MYC/BCL2/BCL6-R ["triple hit"], and 21 MYC/BCL6-R). Thirty-six cases were subjected to targeted next-generation sequencing with MSK-IMPACT HEME. We confirm the poor prognosis of HGBCL, with low complete response rates (44%), poor overall survival (59.8% at 2 years), and high rates of CNS relapse (10.1%). Intensive regimens such as dose-adjusted R-EPOCH were associated with improved overall survival compared to R-CHOP-based regimens. Unexpectedly, patients with MYC/BCL6-R disease had increased incidence of CNS relapse and rapid progression to death after relapse; we observed differing cell of origin in these cases compared with BCL2-R disease. In addition, counter to previous reports in diffuse large B-cell lymphoma (DLBCL), HGBCL transformed from low-grade lymphoma was associated with improved survival in our cohort. Mutational profiling of HGBCL cases demonstrated enrichment for mutations associated with DLBCL, particularly germinal center-derived cases, as well as a high proportion of MYC mutations. Our results support the poor prognosis of HGBCL and the recent separation of MYC/BCL6 disease as a distinct clinical entity.
引用
- Healton SE, Uppal M, Galera P, et al. Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma. Blood Adv. 2026. PMID: 42431614. doi:10.1182/bloodadvances.2025018199
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。